← Back to Search

Mobile Intervention for Suicidal Thoughts

N/A

Recruiting

Led By Dimitris Kiosses, PhD

Research Sponsored by Weill Medical College of Cornell University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

50-90 years old

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 6, week 12, week 24

Awards & highlights

Study Summary

This trial will test whether a new mobile intervention can help improve emotion regulation and reduce suicide risk in adults aged 50-90 who have been hospitalized for suicidal ideation or attempt.

Who is the study for?

This trial is for middle-aged and older adults aged 50-90 who have been hospitalized due to suicidal thoughts or attempts. Participants must be able to understand English, not suffer from severe cognitive impairments (MMSE > 24), psychotic disorders, dementia, or acute medical illnesses.Check my eligibility

What is being tested?

The study tests WellPATH-PREVENT, a mobile psychosocial intervention aimed at improving emotion regulation and reducing suicide risk in participants recently discharged after hospitalization for suicide-related issues.See study design

What are the potential side effects?

Since WellPATH-PREVENT is a psychosocial intervention rather than a medication, it may not have typical drug side effects. However, participants might experience emotional discomfort when discussing sensitive topics.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 90 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 6, week 12, week 24

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 6, week 12, week 24

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6, week 12, week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Client Satisfaction with Treatment (CSQ) - R33

Change in Client Satisfaction with Treatment (CSQ) - R61

Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R33

+7 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Proof-of-Concept WellPATH-PREVENT (R61)Experimental Treatment1 Intervention

Group II: Optimized WellPATH-PREVENT (R33)Experimental Treatment1 Intervention

Group III: Attention Control Usual Care (R33)Active Control1 Intervention

The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH

2,783 Previous Clinical Trials

2,689,012 Total Patients Enrolled

5 Trials studying Suicide Attempt

28,921 Patients Enrolled for Suicide Attempt

Weill Medical College of Cornell UniversityLead Sponsor

1,054 Previous Clinical Trials

1,316,437 Total Patients Enrolled

Dimitris Kiosses, PhDPrincipal InvestigatorWeill Medical College of Cornell University

6 Previous Clinical Trials

500 Total Patients Enrolled

Media Library

Optimized WellPATH-PREVENT Clinical Trial Eligibility Overview. Trial Name: NCT05183230 — N/A

Suicide Attempt Research Study Groups: Proof-of-Concept WellPATH-PREVENT (R61), Optimized WellPATH-PREVENT (R33), Attention Control Usual Care (R33)

Suicide Attempt Clinical Trial 2023: Optimized WellPATH-PREVENT Highlights & Side Effects. Trial Name: NCT05183230 — N/A

Optimized WellPATH-PREVENT 2023 Treatment Timeline for Medical Study. Trial Name: NCT05183230 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this research study for participants?

"Per clinicaltrials.gov, this medical trial is presently seeking participants to participate in its study. It was originally posted on April 22nd 2022 and the details were most recently updated on May 17th of the same year."

Answered by AI

Who is able to register for this investigation?

"The requirements to enroll in this research study include having engaged in parasuicide and being between the ages of 50-90 years old. 115 individuals will be accepted into this trial."

Answered by AI

What is the participant pool size for this clinical trial?

"Affirmative, clinicaltrials.gov displays that this medical experiment is still enrolling patients. It was originally posted on April 22nd 2022 and most recently updated on May 17th of the same year. 115 participants are required from 2 different sites for this trial to complete its objectives."

Answered by AI